Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 2c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.45), $0.02 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $480 thousand versus the consensus estimate of $1.44 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral
• Pfizer reaffirms 2026 guidance after CFO transition news